Shots:
- CytoReason reports the initiation of a project with Sanofi by utilizing its cell-centered models and deconvolution techniques to counsel mechanistic insights for each asthma endotype
- The focus of the project is to drive a better understanding of heterogeneity in asthma patients and identify stable and reproducible asthma endotypes alongwith associated diagnostic features by using minimally invasive procedures
- CytoReason’s AI platform will utilize to treat moderate to severe asthma and overlaying samples from adults and children
Click here to read full press release/ article | Ref: PR Newswire | Image: Business Wire
The post CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma first appeared on PharmaShots.
